Biome Australia (BIO) investor relations material

Financial performance and growth

• Achieved record H1 revenue of AUD 12.4 million, up 40% year-on-year, with net profit up 172% to AUD 1.18 million and gross margin maintained above 60%.

• Eight consecutive quarters of EBITDA growth, with adjusted EBITDA at AUD 1.47 million and strong operating cash flow turnaround.

• EPS increased to AUD 0.53, up 165% year-on-year.

• Revenue compounded at 86% annually from FY20 to FY25, with FY25 revenue at AUD 18.4 million and first full-year net profit.

• Earnings are growing over four times faster than revenue, demonstrating strong operating leverage.

Market position and expansion

• Holds the #1 position by revenue in community pharmacy and is the fastest-growing probiotic brand in Australia.

• Distribution footprint expanded from 100 to 7,500 points of sale, targeting 8,000 by FY27.

• International presence in five markets, with international sales up 69% in FY25 and further expansion planned.

• Market share in pharmacy channel is about 10%, with significant headroom for further growth in a $600m Australian probiotics market.

• Cautious approach to China due to regulatory risks; focus remains on developed markets.

Strategic initiatives and manufacturing

• Announced onshoring of manufacturing in Australia, expected to deliver 65%+ gross margin by FY 2027 and release working capital.

• Onshoring will reduce inventory lead times, improve working capital, and enable smaller, more frequent production batches.

• Australian Made status is a key differentiator for international expansion.

• Strategic partnerships with major pharmacy groups like TerryWhite Chemmart and Priceline are driving growth.

• Near-term catalysts include a major winter immunity campaign, international scaling, and new category launches.